RE: Very nice :)15 May 2019 08:08
Aim4u Godd morning excellent RNS Dr Dan Gooding, CEO of Nuformix, said: "We're delighted to have reached this second pre-clinical milestone. The data generated was not only sufficient to trigger a second payment of £500k with NewsummitBio, but also gave us tremendous confidence to make the next step into human studies. We look forward to sharing human data very soon and continue to work closely with NSB, such is their commitment to the commercialisation of NXP001 and its understanding of the commercial opportunity in China. Milestone revenues continue to validate Nuformix's business model and its commitment to reinvest early revenues back into R&D, avoiding further fund-raising at this stage whilst maximising the potential value of its cocrystal platform."